MLTX vs. QGEN, VTRS, ASND, MRNA, BBIO, BPMC, VRNA, ROIV, ELAN, and RVMD
Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Moderna (MRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.
MoonLake Immunotherapeutics vs. Its Competitors
Qiagen (NYSE:QGEN) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.
Qiagen presently has a consensus price target of $49.40, suggesting a potential upside of 4.02%. MoonLake Immunotherapeutics has a consensus price target of $74.50, suggesting a potential upside of 56.84%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Qiagen.
Qiagen has a net margin of 4.68% compared to MoonLake Immunotherapeutics' net margin of 0.00%. Qiagen's return on equity of 14.61% beat MoonLake Immunotherapeutics' return on equity.
In the previous week, Qiagen had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 4 mentions for Qiagen and 3 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.89 beat Qiagen's score of 0.33 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.
70.0% of Qiagen shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Qiagen has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Qiagen has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.
Summary
Qiagen beats MoonLake Immunotherapeutics on 8 of the 15 factors compared between the two stocks.
Get MoonLake Immunotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MoonLake Immunotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MLTX) was last updated on 7/8/2025 by MarketBeat.com Staff
